| Capture Hi-C identifies putative target genes at 33 breast cancer risk loci JS Baxter, OC Leavy, NH Dryden, S Maguire, N Johnson, V Fedele, ... Nature communications 9 (1), 1028, 2018 | 111 | 2018 |
| Resistance to DNA repair inhibitors in cancer JS Baxter, D Zatreanu, SJ Pettitt, CJ Lord Molecular Oncology 16 (21), 3811-3827, 2022 | 37 | 2022 |
| Elucidating prostate cancer behaviour during treatment via low-pass whole-genome sequencing of circulating tumour DNA S Sumanasuriya, G Seed, H Parr, R Christova, L Pope, C Bertan, ... European urology 80 (2), 243-253, 2021 | 37 | 2021 |
| Identifying high-confidence capture Hi-C interactions using CHiCANE EM Holgersen, A Gillespie, OC Leavy, JS Baxter, A Zvereva, G Muirhead, ... Nature Protocols 16 (4), 2257-2285, 2021 | 14 | 2021 |
| Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element JS Baxter, N Johnson, K Tomczyk, A Gillespie, S Maguire, R Brough, ... The American Journal of Human Genetics 108 (7), 1190-1203, 2021 | 10 | 2021 |
| MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells A Zelceski, P Francica, L Lingg, M Mutlu, C Stok, M Liptay, J Alexander, ... Cell reports 42 (5), 2023 | 3 | 2023 |
| PPP2R1A missense mutations as a novel biomarker of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma J Stewart, J Baxter, D Zatreanu, R Brough, F Song, A Konde, D Krastev, ... European Journal of Cancer 174, S99, 2022 | 1 | 2022 |
| 3P Identification of novel biomarkers of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma JR Stewart, J Baxter, D Zatreanu, R Brough, F Song, A Konde, D Krastev, ... Annals of Oncology 33, S383-S384, 2022 | 1 | 2022 |
| Cancer‐associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7 JS Baxter, R Brough, DB Krastev, F Song, S Sridhar, A Gulati, J Alexander, ... Molecular Oncology 18 (2), 369-385, 2024 | | 2024 |
